Setmelanotide

Overview

A precision-medicine peptide. It restores signalling in a specific broken hypothalamic pathway, and in the right genetic patient the effect is dramatic. In everyone else, it does very little — a useful reminder that peptides are not interchangeable.

How it works

Agonises MC4R downstream of the leptin-melanocortin pathway. In patients whose obesity stems from an upstream defect (POMC, PCSK1, LEPR) or from ciliopathy-related signalling failure, bypassing the lesion restores satiety signalling.

Evidence base

Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.

• Small trials by design — the target populations are ultra-rare — but with unambiguous effect sizes.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

• Large weight loss in genetically defined obesity Strong evidence

  Most patients with POMC or LEPR deficiency achieved 10% or greater weight loss at one year, in a population previously considered untreatable.

• Marked hunger reduction Strong evidence

  Patient-reported hyperphagia scores fell substantially, which for these families is often more meaningful than the weight number.

• Clear genetic selection criteria Strong evidence

  Confirmatory genetic testing identifies responders before treatment, avoiding open-ended trials of therapy.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

• Skin hyperpigmentation Moderate evidence

  Very common, because MC1R cross-activation increases melanin. New or darkening naevi need dermatologic assessment.

• Depression and suicidal ideation warning Serious

  Labelled warning requiring psychiatric monitoring, particularly in adolescents.

• Spontaneous penile erections Minor

  A predictable melanocortin class effect; reported in a substantial minority of male patients.

• Injection-site reactions and nausea Minor

  Common but usually manageable.

• No benefit in common polygenic obesity Moderate evidence

  It is not a general weight-loss drug and should not be sought as one.

Who should avoid it

• Patients without a qualifying genetic diagnosis
• Pregnancy
• Untreated significant depression (relative)

If used under medical supervision, monitor

• Full skin examination before and during treatment
• Depression screening
• Weight and hyperphagia scores
• Growth in pediatric patients

Interactions

Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.

• No major pharmacokinetic interactions established
• Other melanocortin agonists — additive pigmentation and cardiovascular effects

Commonly confused with

These mix-ups cause real harm — two products sold under one name, or two molecules whose effects run in opposite directions.

Regulatory & legal status

Prescription drug restricted to labelled genetic indications.

Infographic

Setmelanotide — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

• PubMed — all published literature on Setmelanotide
• PubMed — randomized controlled trials only
• ClinicalTrials.gov — registered human trials
• DailyMed — official FDA prescribing information

Related peptides in Metabolic & Weight